Twitxy Saved

Manni Mohyuddin

Verified account This account is verified. Learn more

@ManniMD1

Cancer doctor with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. Views own.
Salt Lake City, UT Joined June 2020
450 Following 13K Followers 7.8K Posts

Latest posts 5

Pinned post

Manni Mohyuddin Verified account @ManniMD1
For those that just followed me:
I tweet about plasma cell disorders. I feel strongly about end-of-life, medical education and calling out what I feel is wrong (such as bad control arms, hype etc)
I write educational 🧵occasionally- compiled here👇
https://t.co/7RpUkh02NX
#mmsm
Manni Mohyuddin Verified account @ManniMD1
👌🏽👌🏽👌🏽

To say that belantamab does not impair quality of life is ridiculous. It speaks to the imperfection of how we assess and report quality of life.

Unfortunate that some obvious truths have to be clearly pointed out this way.

@AaronGoodman33
Shycollie Verified account @shycollie Aug 2, 2024
@AaronGoodman33 For me, this drug is dead on arrival because eye toxicity is awful for anyone, really quality of life limiting and dangerous. In the real world lots of patients have weird insurance, Medicaid so quick access to top flight ophthalmologists interested in these pts is too limited
View quoted post on X
9 replies 4 reposts 43 likes 13K views View on X
Manni Mohyuddin Verified account @ManniMD1
NEJM is the best journal in our field.

I did expect a more nuanced editorial and was a little disappointed to see this.

Belantamab is indeed defying expectations and turning out to be better than expected.

However....

⭐️The fact that quality of life was not reported as being worse is an indictment of quality of life instruments and reporting (and attrition on their completion rate) rather than belantamab having no effect on quality of life.
⭐️Belantamab isnt quite as convenient and "easy to administer" as the authors listed. Frequent eye exams are inconvenient, and the drug profoundly impacts quality of life in ways instruments don't capture.
⭐️No mention on censoring, and that the control arm (Dara/Velcade/dex) underperformed relative to earlier trials.

A last note- shouldnt the NEJM have a policy to not accept editorials from people with consulting payments for the drug in question? I say this in the politest way I can and this is not personal (its a broader problem), but for the integrity of science, we should abstain from writing editorials in top-notch journals for drugs we take personal payments for.

nejm.org/doi/pdf/10.105…
8 replies 18 reposts 126 likes 56K views View on X
Manni Mohyuddin Verified account @ManniMD1
Actually, Aaron has many papers/trials too.

I am biased, but my favorite paper of his one we wrote together in which we highlighted the epidemic of over-treatment of myeloma and its precursor states.

Heres a non paywalled link to it:

drive.google.com/file/d/1wPINXf…
Manni Mohyuddin Verified account @ManniMD1 Aug 1, 2024
Happy to see this piece on @AaronGoodman33 in @TheLancetHaem.

A well deserved accolade.

Greatness isn’t defined by the n of papers/trials you have, but by taking good care of pts, and being a great husband/father/friend. And that’s what Aaron is!

thelancet.com/journals/lanha…
View quoted post on X